Fidelity Advisor Biotechnology I (FBTIX)

Fund Assets	2.35B
Expense Ratio	0.669%
Min. Investment	$0.00
Turnover	54.00%
Dividend (ttm)	0.47
Dividend Yield	0.95%
Dividend Growth	-45.01%
Payout Frequency	Annual
Ex-Dividend Date	Dec 26, 2025

Previous Close	49.29
YTD Return	21.58%
1-Year Return	32.41%
5-Year Return	68.14%
52-Week Low	37.73
52-Week High	57.68
Beta (5Y)	0.48
Holdings	131
Inception Date	Dec 27, 2000

About FBTIX

Fidelity Advisor Biotechnology I is an actively managed mutual fund focused on the biotechnology sector. The fund primarily seeks capital appreciation by investing at least 80% of its assets in companies engaged in the research, development, manufacture, and distribution of biotechnological products, services, and processes. These holdings include firms that benefit from significant scientific and technological advances within the biotechnology industry. The portfolio is concentrated in both domestic and international issuers, relying on rigorous fundamental analysis of each issuer’s financial health, industry standing, and broader economic conditions. With a substantial allocation to industry leaders such as AbbVie, Amgen, and Regeneron Pharmaceuticals, the fund is non-diversified, emphasizing select opportunities in biotech innovation. Managed by a specialized team leveraging deep scientific and clinical expertise, Fidelity Advisor Biotechnology I plays a specialized role in the market by offering investors targeted exposure to one of the most dynamic and research-driven segments of healthcare. The fund is frequently used by institutions and investors for tactical or strategic allocation to capture long-term growth trends driven by advancements in medical technology and drug development.

• Fund Family: Fidelity
• Category: Health
• Performance Rating: High
• Risk Rating: Above Average
• Stock Exchange: Nasdaq
• Ticker Symbol: FBTIX
• Share Class: Class I
• Index: S&P 500 TR

Performance

FBTIX had a total return of 32.41% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.79%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
FIJYX	Class Z	0.57%
FBTAX	Class A	0.94%
FBTTX	Class M	1.19%
FBTCX	Class C	1.69%

Top 10 Holdings

46.21% of assets

Name	Symbol	Weight
AbbVie Inc.	ABBV	13.83%
Gilead Sciences, Inc.	GILD	6.02%
Alnylam Pharmaceuticals, Inc.	ALNY	3.84%
Insmed Incorporated	INSM	3.41%
Amylyx Pharmaceuticals, Inc.	AMLX	3.38%
argenx SE	ARGX	3.28%
Dianthus Therapeutics, Inc.	DNTH	3.18%
Spyre Therapeutics, Inc.	SYRE	3.16%
Moderna, Inc.	MRNA	3.12%
Revolution Medicines, Inc.	RVMD	2.98%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 26, 2025	$0.572	Dec 29, 2025
Dec 26, 2024	$1.699	Dec 27, 2024
Dec 21, 2023	$0.407	Dec 22, 2023
Dec 17, 2021	$5.411	Dec 20, 2021
Jul 9, 2021	$0.135	Jul 12, 2021
Dec 18, 2020	$2.917	Dec 21, 2020

Data Sources: Tiingo, Financial Modeling Prep, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Oct 16, 2026

Data Sources Report a data error